These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 19701690)

  • 1. Calcium, phosphate and parathyroid metabolism in kidney transplanted patients.
    Ambrus C; Molnar MZ; Czira ME; Rosivall L; Kiss I; Remport A; Szathmari M; Mucsi I
    Int Urol Nephrol; 2009 Dec; 41(4):1029-38. PubMed ID: 19701690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International variation in the management of mineral bone disorder in patients with chronic kidney disease: Results from CKDopps.
    Liabeuf S; McCullough K; Young EW; Pisoni R; Zee J; Reichel H; Pecoits-Filho R; Port FK; Stengel B; Csomor PA; Metzger M; Robinson B; Massy ZA
    Bone; 2019 Dec; 129():115058. PubMed ID: 31493530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Status of Serum Calcium, Phosphate and Intact Parathyroid Hormone in Predialysis Chronic Kidney Disease Patients of Stage-3 to Stage-5 Compared To KDOQI Guideline.
    Hai AA; Rahman MM; Anwar MR; Miah OF; Latif A; Jalil ME; Razzak MA; Morshed AM; Mahmud H; Dowel FA
    Mymensingh Med J; 2021 Oct; 30(4):1031-1042. PubMed ID: 34605474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23?
    Wesseling-Perry K; Tsai EW; Ettenger RB; Jüppner H; Salusky IB
    Nephrol Dial Transplant; 2011 Nov; 26(11):3779-84. PubMed ID: 21441401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profile of chronic kidney disease related-mineral bone disorders in newly diagnosed advanced predialysis diabetic kidney disease patients: A hospital based cross-sectional study.
    Ray S; Beatrice AM; Ghosh A; Pramanik S; Bhattacharjee R; Ghosh S; Raychaudhury A; Mukhopadhyay S; Chowdhury S
    Diabetes Metab Syndr; 2017 Dec; 11 Suppl 2():S931-S937. PubMed ID: 28728874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study.
    Gallieni M; De Luca N; Santoro D; Meneghel G; Formica M; Grandaliano G; Pizzarelli F; Cossu M; Segoloni G; Quintaliani G; Di Giulio S; Pisani A; Malaguti M; Marseglia C; Oldrizzi L; Pacilio M; Conte G; Dal Canton A; Minutolo R
    J Nephrol; 2016 Feb; 29(1):71-8. PubMed ID: 25986389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of tubular reabsorption of phosphate as a surrogate marker for phosphate regulation in chronic kidney disease.
    Hong YA; Lim JH; Kim MY; Kim Y; Yang KS; Chung BH; Chung S; Choi BS; Yang CW; Kim YS; Chang YS; Park CW
    Clin Exp Nephrol; 2015 Apr; 19(2):208-15. PubMed ID: 24682550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
    Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N
    Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of weekly administration of cholecalciferol on parathyroid hormone in stable kidney-transplanted patients with CKD stage 1-3.
    Sella S; Bonfante L; Fusaro M; Neri F; Plebani M; Zaninotto M; Aghi A; Innico G; Tripepi G; Michielin A; Prandini T; Calò LA; Giannini S
    Clin Chem Lab Med; 2020 May; 59(2):343-351. PubMed ID: 32374278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achieving chronic kidney disease treatment targets in renal transplant recipients: results from a cross-sectional study in Spain.
    Marcén R; del Castillo D; Capdevila L; Fernandez-Fresnedo G; Rodrigo E; Cantarell C; Fernández-Rodriguez A; López-Oliva MO; Camps J; Aljama P; Ortuño J; Arias M
    Transplantation; 2009 May; 87(9):1340-6. PubMed ID: 19424034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parathyroid hormone and clinical outcome in kidney transplant patients with optimal transplant function.
    Bleskestad IH; Bergrem H; Leivestad T; Hartmann A; Gøransson LG
    Clin Transplant; 2014 Apr; 28(4):479-86. PubMed ID: 25649861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Management of bone and mineral metabolism disorders before the dialysis stage remains still perfectible. Data from the French Phosphorus and Calcium Survey Photo-Graphe].
    Jean G; Daugas É; Roth H; Drueke T; Bouchet JL; Hannedouche T; London G; Fouque D
    Nephrol Ther; 2017 Nov; 13(6):470-478. PubMed ID: 28843391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal transplant and secondary hyperparathyroidism.
    Gøransson LG; Bergrem H
    Scand J Urol Nephrol; 2007; 41(6):553-7. PubMed ID: 18050015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microscopic nephrocalcinosis in chronic kidney disease patients.
    Evenepoel P; Daenen K; Bammens B; Claes K; Meijers B; Naesens M; Sprangers B; Kuypers D; Lerut E
    Nephrol Dial Transplant; 2015 May; 30(5):843-8. PubMed ID: 25586405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone mineral disorders in pediatric and adolescent renal transplant recipients.
    Derakhshan A; Behbahan AG; Lotfi M; Omrani GH; Fallahzadeh MH; Basiratnia M; Al-Hashemi GH
    Pediatr Transplant; 2011 Jun; 15(4):367-75. PubMed ID: 21429060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.
    Craver L; Marco MP; Martínez I; Rue M; Borràs M; Martín ML; Sarró F; Valdivielso JM; Fernández E
    Nephrol Dial Transplant; 2007 Apr; 22(4):1171-6. PubMed ID: 17205962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.
    Bover J; Ureña-Torres P; Lloret MJ; Ruiz-García C; DaSilva I; Diaz-Encarnacion MM; Mercado C; Mateu S; Fernández E; Ballarin J
    Expert Opin Pharmacother; 2016 Jun; 17(9):1247-58. PubMed ID: 27156993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic kidney disease-mineral bone disease in elderly chronic kidney disease patients.
    Kanda E; Yoshida M; Sasaki S
    BMC Nephrol; 2012 Sep; 13():122. PubMed ID: 23013306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.